VZV ORF29p protein-related compositions and methods

Abstract

The present invention provides compositions of matter comprising 29p protein having bound thereto an agent whose delivery into a eukaryotic cell is desired. The present invention also provides a monoclonal antibody which specifically binds to 29p protein. The present invention further provides methods for delivering an agent into a eukaryotic cell, and methods for causing a eukaryotic cell to secrete a desired protein in the form of a fusion protein. The present invention further provides 29p protein-containing pharmaceutical compositions. The present invention still further provides nucleic acid molecules which hybridize to at least a portion of a nucleic acid molecule encoding 29p protein. Finally, the present invention provides methods for detecting the presence of, and quantitatively determining the amount of, a 29p protein-encoding nucleic acid molecule in a sample.

Description

BACKGROUND OF THE INVENTION

Throughout this application, various publications are referenced by arabic numbers within parentheses. Disclosures of these publications in their entirety are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

Varicella-Zoster Virus (“VZV”) infects dorsal root ganglia (“DRG”), enters latency, and may later reactivate to cause zoster. Studies have detected VZV in specific sites at different stages of infection. VZV DNA is present in the oropharynx (27) and in peripheral blood mononuclear cells (“PBMCs”) of patients with chickenpox (3, 16, 20). Virus DNA, the glycoproteins gE and gB, and the immediate-early protein 63 (“IE63p”) are found in skin biopsy samples obtained from patients with chickenpox or zoster (1, 23-25). VZV is found in keratinocytes, antigen-presenting cells, and endothelial cells during acute zoster (23, 25) and in keratinocytes and inflammatory cells during chickenpox (1). VZV is present in neurons and satellite cells of DRG years following primary infection (6-8, 12, 17, 22) and has been observed by electron microscopy in sensory nerves during zoster (10). Other details of VZV pathogenesis remain speculative, including how the virus spreads from respiratory epithelial cells to PBMCs, keratinocytes, and DRG. Because PBMCs, sensory nerves, and epithelial cells are in close proximity in the dermis and epidermis, the skin is likely the site where this virus enters the nervous system.

By analogy with herpes simplex virus (“HSV”), it is thought that VZV transcription is temporally regulated. Immediate-early (“IE”) genes are expressed first, followed by early (“E”) genes and lastly late (“L”) genes (5). Some VZV proteins encoded by IE and L genes are incorporated in the virion, including trans-activators such as IE63p and structural proteins such as gC (14, 15). ORF29p (for open reading frame 29 protein), the major VZV DNA-binding protein, is encoded by a putative E gene and is not detected in purified virions (13). ORF29p is also referred to herein as “29p protein”, “ORF29p protein”, and “VZV ORF29p protein.” During latency, VZV exhibits limited gene expression (6-9, 22), with the accumulation of specific IE and E gene-encoded proteins in neurons (18, 19). During reactivation, all kinetic classes of VZV genes are expressed in neurons (18). Whether VZV is in the lytic or latent state is reflected by the localization of expressed VZV gene products. VZV IE and E proteins that are present in both the nucleus and cytoplasm during productive infection are detected only in the cytoplasm of neurons during latency (18).

Early observations suggested that there were inclusion bodies in endothelial cells present in varicella lesions (29). However, there was no known association between VZV histology and viral etiology at that time.

SUMMARY OF THE INVENTION

The present invention provides a first composition of matter comprising 29p protein having bound thereto an agent whose delivery into a eukaryotic cell is desired, which composition of matter enters the cell upon contact therewith.

The present invention also provides a second composition of matter comprising a 29p protein having operably affixed thereto a lipid-soluble moiety which permits the protein to be anchored to a lipid membrane.

The present invention also provides a lipid vesicle comprising the second composition of matter anchored thereto via its lipid-soluble moiety, such that the 29p protein is situated on the vesicle's outer surface and facilitates delivery of the vesicle's contents into a eukaryotic cell when the vesicle is contacted therewith. The present invention further provides a monoclonal antibody which specifically binds to 29p protein.

The present invention further provides a method for delivering an agent into a eukaryotic cell comprising contacting the agent with the cell, wherein the agent has bound thereto 29p protein which enters the cell upon contact therewith, thereby delivering the agent into the cell.

The present invention further provides a method for causing a eukaryotic cell to secrete a desired protein in the form of a fusion protein, comprising introducing into the cell a vector for expressing a fusion protein that comprises the desired protein and 29p protein operably affixed thereto, whereby the cell expresses the fusion protein and the 29p protein thereof permits the fusion protein's exit from the cell, thereby causing the cell to secrete the desired protein in the form of a fusion protein.

The present invention further provides a pharmaceutical composition comprising (a) a composition of matter comprising 29p protein having bound thereto a therapeutic or prophylactic agent, which composition of matter enters a eukaryotic cell upon contact therewith, and (b) a pharmaceutically acceptable carrier.

The present invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a lipid vesicle comprising (a) a therapeutic or prophylactic agent therein, and (b) a 29p protein having operably affixed thereto a lipid-soluble moiety, which protein (i) is anchored to the vesicle via its lipid-soluble moiety, (ii) is situated on the vesicle's outer surface, and (iii) facilitates delivery of the agent into a eukaryotic cell when the vesicle is contacted therewith.

The present invention further provides a method for treating a subject afflicted with a disorder comprising administering to the subject a therapeutically effective amount of the first or second pharmaceutical composition, wherein the therapeutic agent therein is known to ameliorate the disorder.

The present invention further provides a method for inhibiting the onset of a disorder in a subject comprising administering to the subject a prophylactically effective amount of the first or second pharmaceutical composition, wherein the prophylactic agent therein is known to inhibit the disorder's onset.

The present invention further provides a nucleic acid molecule which hybridizes to at least a portion of a nucleic acid molecule encoding 29p protein.

The present invention further provides a method for detecting the presence of a 29p protein-encoding nucleic acid molecule in a sample comprising the steps of (a) contacting the sample with the instant detectable nucleic acid molecule under conditions permitting it to hybridize to a 29p protein-encoding nucleic acid molecule if present in the sample, and (b) detecting the presence of any detectable nucleic acid molecule so hybridized, thereby detecting the presence of a 29p protein-encoding nucleic acid molecule in the sample.

Finally, the present invention provides a method for quantitatively determining the amount of 29p protein-encoding nucleic acid molecule in a sample comprising the steps of (a) contacting the sample with the instant detectable nucleic acid molecule under conditions permitting it to hybridize to any 29p protein-encoding nucleic acid molecule present in the sample, (b) quantitatively determining the amount of detectable nucleic acid molecule so hybridized, and (c) comparing this amount to a known standard, thereby quantitatively determining the amount of 29p protein in the sample.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 . Immunohistochemical detection of ORF29p in skin biopsy samples. Chickenpox (A), zoster (B), and Grover's disease (C) skin lesions were analyzed for ORF29p as previously described (18), with the following exceptions. All washes were performed in Tris-buffered saline, and the signal was developed for 10 min in AP substrate (Vector Laboratories, Inc., Burlingame, Calif.), according to the manufacturer's recommendations, in the presence of levamisole to inhibit endogenous alkaline phosphatase activity. Arrows indicate positive epithelial cells. Magnification, ×100.

FIG. 2 . Immunohistochemical detection of ORF29p and CD43 in skin biopsy samples. Skin biopsy samples from a patient with chickenpox (A and B) or a patient with zoster (C and D) were probed for the presence of ORF29p (A and C) or ORF29p and CD43 (B and D) as described in the legend to FIG. 1 . Gray arrows indicate endothelial cells containing ORF29p. Black arrows indicate cells expressing CD43 that contain ORF29p. Magnification, ×600.

FIG. 3 . Immunohistochemical detection of ORF29D and gC in skin biopsy samples. Sections of nerves in the dermis underlying chickenpox (A and B) or zoster (C and D) lesions underwent immunohistochemistry for ORF29p (A and C) or gC (B and D) as described in the legend to FIG. 1 . Magnification, ×400.

FIG. 4 . Western blot analyses of VZV and HSV-1 proteins. ORF29p, ORF21p, and ICP8 were detected in mock-infected cell extracts (M Cell) and supernatants (M Sup) or cell extracts (I Cell) and supernatants (I Sup) infected with the viruses denoted on the left. The proteins were immunoprecipitated and detected using the antibodies denoted on the right. Arrowheads denote the proteins of interest.

FIG. 5 . Immunohistochemical detection of ORF29p in hNTs. hNTs treated with VZV-infected cell supernatants and LysoTracker were analyzed by immunohistochemistry for the presence of ORF29p. Gray arrows indicate ORF29p (A), LysoTracker (B), and colocalization of ORF29p and LysoTracker in the merged image (C). White arrows indicate an endocytic vesicle that does not contain ORF29p (B and C). ORF29p is restricted to cyptoplasmic vesicles in the treated hNTs (D). Untreated hNTs do not contain ORF29p (E).

FIG. 6 . Protein and nucleotide sequences. ORF29p amino acid sequence and nucleotide sequence encoding it.

DETAILED DESCRIPTION OF THE INVENTION

This invention is based on the surprising discovery that the Varicella-Zoster Virus protein ORF29p can readily enter and exit eukaryotic cells. This unusual property renders it advantageous as, among other things, a vehicle for delivering agents to, and secreting them from, eukaryotic cells.

Specifically, the present invention provides a first composition of matter comprising 29p protein having bound thereto an agent whose delivery into a eukaryotic cell is desired, which composition of matter enters the cell upon contact therewith.

As used herein, the term “29p protein” shall mean the protein having the sequence identified in FIG. 6 or a naturally-occurring variant thereof. As stated above, “29p protein” is alternatively referred to herein as “ORF29p”, “ORF29p protein”, and “VZV ORF29p protein.”

The agent of the first composition can be of any physical category. In one embodiment, the agent is a protein or a peptide. In another embodiment, the agent is a nucleic acid molecule. In a further embodiment, the agent is an organic compound.

An agent that is a “protein” is a polypeptide sequence greater than 10 amino acids in length. An agent that is a “peptide” is a polypeptide having a sequence less than or equal to 10 amino acids in length. Examples of protein agents include, for example, insulin, factors VIII and IX, proteases, alpha-glucosidase, glucocerebrosidase, adenosine deaminase, and DNAase.

An agent that is a “nucleic acid molecule” can be any nucleic acid molecule, including, without limitation, DNA (e.g., cDNA and genomic DNA), RNA (e.g., mRNA and rRNA), and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T, and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, N.J., USA). “Nucleic acid molecules” further include, without limitation, antisense, expression vectors, and catalytic nucleic acids such as ribozymes and DNAzymes.

Organic compounds include, without limitation, nutrients such as vitamins, and organic pharmaceuticals such as analgesics, anesthetics, anticonvulsants, antidiabetic agents, anti-infective agents, antineoplastics, gastrointestinal agents, immunosuppressives, parasympatholytics, and parasympathomimetics. Other organic compounds are well known in the art (see, e.g., Physician's Desk Reference, 53rd ed., 1999).

In the first composition of matter, the agent can be “bound” to the 29p protein either covalently or non-covalently. Examples of covalent binding include, without limitation, N-terminal and/or C-terminal fusion proteins in the case of protein or peptide agents, and peptide or other chemical linkages in the case of agents that are nucleic acids or organic molecules. Methods of forming covalent bonds between proteins, proteins and nucleic acid molecules, and proteins and organic molecules are routine in the art. In addition the agent can be bound to the 29p protein non-covalently. Examples of non-covalent bonds include, for example, those between 29p protein and an antibody directed thereto.

Delivery of the agent into a cell can be for any purpose, e.g., therapeutic, prophylactic, diagnostic, and labeling. As used herein, an entity is “delivered” into a eukaryotic cell if it traverses the cell membrane and enters the cytoplasm, nucleus, or other organelle thereof. Mechanisms of entry include, without limitation, cellular endocytosis.

The eukaryotic cell into which the instant composition is delivered can be any eukaryotic cell. In the preferred embodiment, the eukaryotic cell is a mammalian cell, e.g., a murine or human cell. Eukaryotic cells include, without limitation, Hela cells, fibroblasts, astrocytes, neurons, NB41 cells, and SupT-1 cells. Conditions under which the instant composition of matter will enter a eukaryotic cell include, for example, physiological conditions.

The present invention also provides a second composition of matter comprising a 29p protein having operably affixed thereto a lipid-soluble moiety which permits the protein to be anchored to a lipid membrane.

The present invention further provides a lipid vesicle comprising the second composition of matter anchored thereto via its lipid-soluble moiety, such that the 29p protein is situated on the vesicle's outer surface and facilitates delivery of the vesicle's contents into a eukaryotic cell when the vesicle is contacted therewith. In the preferred embodiment, the vesicle's contents comprise an agent whose delivery into a cell is desired.

As used herein, the term “lipid-soluble moiety” shall mean an entity such as a hydrophobic polypeptide chain or a phospholipid capable of integrating within a lipid bilayer membrane. In one embodiment, the lipid-soluble moiety comprises a polypeptide chain bound to the N- or C-terminus of the 29p protein. Such fusion proteins can be made using known methods. The lipid-soluble moiety is “operably affixed” to the 29p protein if it does not interfere with the 29p protein's ability to enter a eukaryotic cell when contacted therewith. The second composition of matter is “anchored to a lipid membrane” in that it is immobilized with respect to the lipid membrane due to the lipid-soluble moiety's integration therein. Finally, as used herein, a vesicle's “contents” shall mean everything in or on the vesicle except the vesicle membrane and 29p protein anchored thereto.

The present invention also provides a monoclonal antibody which specifically binds to 29p protein. In one embodiment, the monoclonal antibody is labeled with a detectable marker. As used herein, the term “antibody” includes, without limitation, murine, human and humanized antibodies, and antigen-binding fragments thereof. Methods of generating monoclonal antibodies are wellknown (30).

The present invention further provides a method for delivering an agent into a eukaryotic cell comprising contacting the agent with the cell, wherein the agent has bound thereto 29p protein which enters the cell upon contact therewith, thereby delivering the agent into the cell.

The present invention further provides a method for causing a eukaryotic cell to secrete a desired protein in the form of a fusion protein, comprising introducing into the cell a vector for expressing a fusion protein that comprises the desired protein and 29p protein operably affixed thereto, whereby the cell expresses the fusion protein and the 29p protein thereof permits the fusion protein's exit from the cell, thereby causing the cell to secrete the desired protein in the form of a fusion protein. As used herein, the “secretion” of a protein by a cell shall mean the exit of that protein from the cell by any means. Expression vectors useful for carrying out the instant method are well known in the art (30).

As used herein, the term “fusion protein” shall mean a protein having a plurality of regions, each corresponding to a distinct protein or fragment thereof. Fusion proteins can include linker regions connecting the regions thereof, which are known in the art.

The present invention further provides a first pharmaceutical composition comprising (a) a composition of matter comprising 29p protein having bound thereto a therapeutic or prophylactic agent, which composition of matter enters a eukaryotic cell upon contact therewith, and (b) a pharmaceutically acceptable carrier.

The present invention further provides a second pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a lipid vesicle comprising (a) a therapeutic or prophylactic agent therein, and (b) a 29p protein having operably affixed thereto a lipid-soluble moiety, which protein (i) is anchored to the vesicle via its lipid-soluble moiety, (ii) is situated on the vesicle's outer surface, and (iii) facilitates delivery of the agent into a eukaryotic cell when the vesicle is contacted therewith.

The present invention further provides a method for treating a subject afflicted with a disorder comprising administering to the subject a therapeutically effective amount of the first or second pharmaceutical composition, wherein the therapeutic agent therein is known to ameliorate the disorder.

The present invention further provides a method for inhibiting the onset of a disorder in a subject comprising administering to the subject a prophylactically effective amount of the first or second pharmaceutical composition, wherein the prophylactic agent therein is known to inhibit the disorder's onset.

As used herein, “subject” shall mean any animal, such as a primate, mouse, rat, guinea pig, or rabbit. In the preferred embodiment, the subject is a human.

As used herein, “inhibiting the onset of a disorder” shall mean either lessening the likelihood of the disorder's onset, or preventing the onset of the disorder entirely. In the preferred emmbodiment, inhibiting the onset of a disorder means preventing its onset entirely.

As used herein, “treating” a disorder shall mean slowing, stopping, or reversing the disorder's progression. In the preferred embodiment, “treating” a disorder means reversing the disorder's progression, ideally to the point of eliminating the disorder itself. As used herein “ameliorating” and “treating” a disorder are equivalent.

Determining a therapeutically effective or prophylactically effective amount of the pharmaceutical composition can be done based on animal data using routine computational methods. In one embodiment, the therapeutically or prophylactically effective amount is an amount sufficient to deliver to the subject between about 1 μg/kg and 1 g/kg of the 29p protein therein. In another embodiment, the effective amount is an amount sufficient to deliver to the subject between about 100 μg/kg and 100 mg/kg of the 29p protein therein. In another embodiment, the effective amount is an amount sufficient to deliver to the subject between about 1 mg/kg and 10 mg/kg of the 29p protein therein. In another embodiment, the effective amount is an amount sufficient to deliver to the subject between about 10 mg/kg and 100 mg/kg of the 29p protein therein.

In the present invention, administering the instant pharmaceutical compositions can be effected or performed using any of the various methods and delivery systems known to those skilled in the art. The administering can be performed, for example, intravenously, orally, via implant, transmucosally, transdermally, intramuscularly, and subcutaneously. The pharmaceutical carriers used in the instant pharmaceutical compositions are well known to those skilled in the art. The following drug delivery systems, which employ a number of routinely used carriers, are only representative of the many embodiments envisioned for administering the instant composition.

Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g. ethanol, propylene glycol and sucrose) and polymers (e.g. polycaprylactones, and PLGA's). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone.

Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrilodone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).

Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).

Dermal delivery systems are preferred, and include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers, (e.g. fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer. Examples of liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,N I ,N II ,N III -tetramethyl-N,N I ,N II ,N III -tetrapalmityl-spermine and dioleoyl phosphatidyl ethanolamine (DOPE)(GIBCO BRL); (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N-[1-(2,3-dioleoyloxy)-N,N,N-trimethylammonium methylsulfate)(Boehringer Manheim); and (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA and the neutral lipid DOPE (GIBCO BRL). Herein, the term “liposome” and “lipid vesicle” are used interchangebly. In the instant pharmaceutical compositions comprising 29p protein-containing lipid vesicles, the term “pharmaceutically acceptable carrier” refers to carriers other than liposomes.

Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents (e.g., gums, zanthans, cellulosics and sugars), humectants (e.g. sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and chelating agents (e.g., EDTA).

The present invention further provides a nucleic acid molecule which hybridizes to at least a portion of a nucleic acid molecule encoding 29p protein.

In one embodiment, the nucleic acid molecule encoding 29p protein has the sequence shown in FIG. 6 . In a further embodiment, the nucleic acid molecule is complementary to the nucleic acid molecule having the sequence shown in FIG. 6 .

The invention further provides the nucleic acid molecule which hybridizes to at least a portion of a nucleic acid molecule encoding 29p protein, wherein the nucleic acid molecule is labeled with a detectable marker.

The present invention further provides a method for detecting the presence of a 29p protein-encoding nucleic acid molecule in a sample comprising the steps of (a) contacting the sample with the instant detectable nucleic acid molecule under conditions permitting it to hybridize to a 29p protein-encoding nucleic acid molecule if present in the sample, and (b) detecting the presence of any detectable nucleic acid molecule so hybridized, thereby detecting the presence of a 29p protein-encoding nucleic acid molecule in the sample.

Finally, the present invention provides a method for quantitatively determining the amount of 29p protein-encoding nucleic acid molecule in a sample comprising the steps of (a) contacting the sample with the instant detectable nucleic acid molecule under conditions permitting it to hybridize to any 29p protein-encoding nucleic acid molecule present in the sample, (b) quantitatively determining the amount of detectable nucleic acid molecule so hybridized, and (c) comparing this amount to a known standard, thereby quantitatively determining the amount of 29p protein in the sample.

Conditions permitting nucleic acid hybridization are well known in the art and include, without limitation, physiological conditions (30). Detectable markers are known in the art, and include, without limitation, markers utilizing fluorescence and radiolabeling.

The known standard to which the amount of hybridized detectable nucleic acid molecule is compared can be, for example, one or more data points correlating known amounts of 29p protein-encoding nucleic acid molecule with the amounts of detectable nucleic acid molecule that hybridize therewith.

The definitions of terms set forth in the Detailed Description of the Invention are applicable wherever such terms occur herein, unless stated otherwise.

The present invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

Experimental Details

The ORF29p protein is a 131 kdalton protein encoded by a 3612 bp open reading frame in the varicella zoster virus (VZV). On the basis of nucleotide and amino acid homology the protein was predicted to be a homologue of ICP8, a well characterized single-stranded DNA-binding protein from herpes simplex virus (HSV). Subsequent biochemical studies have verified this to be the case VZV and HSV are members of the family alphaherpesviridae.

We demonstrated that ORF29p was detected in peripheral nerves in the dermis in biopsy specimens taken from patients with chicken pox. Because of the role of this protein in the replication of virus DNA, which occurs in the nucleus of infected cells, this was an unexpected finding. When medium from cells infected with HSV or VZV was harvested, clarified by centrifugation and subsequently filtered to remove cells and large debris we were able to demonstrate that ORF29p, but not ICP8, was secreted from tissue culture cells infected in vitro, in vivo, and ex vivo. The clarified supernatants from cells infected with VZV but not HSV contained a protein with the mobility characteristic of ORF29p that reacted with antibody specific for this protein.

Subsequent assays of the filtered tissue culture medium from VZV infected cells demonstrated that the ORF29p protein present in the medium was able to enter cultivated human neurons as evidenced by immunohistochemical analysis. In similar, but unpublished, studies we have demonstrated that ORF29p is assimilated by human lymphocytes. In other unpublished studies, we have shown that recombinant ORF29p, purified from insect cells infected with a baculovirus expressing the protein, is taken up by cultured human neurons and detected in both the cytoplasm and nucleus of these cells.

Thus, ORF29p has the potential to be used as a charon for the delivery of pharmaceuticals to a wide spectrum of human cells. For example, delivery of analgesics coupled to ORF29p to sensory nerves in areas of the body where there is intense local pain could provide local relief. These pharmaceuticals could include biological macromolecules and small molecules such as hormones, growth factors, enzymes, toxins, antiviral agents and chemical compounds to be used as drugs.

EXAMPLE 1

Varicella-Zoster Virus Proteins in Skin Lesions: Implications for a Novel Role of ORF29p in Chickenpox

Skin biopsy samples from varicella-zoster virus (vzv)-infected patients examined by immunohistochemistry demonstrated VZV replication in nonepithelial cell types. ORF29p, a nonstructural nuclear protein, was found in nerves of two of six patients with chickenpox. In tissue culture, ORF29p was secreted by VZV-infected fibroblasts. Extracellular ORF29p can be taken up through endocytosis by human neurons, implying a novel role for this protein in pathogenesis.

To determine if, during primary infection, as in zoster, VZV infects endothelial cells and nerves in the dermis and to characterize the inflammatory cells in the epidermis and dermis infected by VZV, we performed comparative immunohistochemical analyses of skin biopsy samples obtained from patients with chickenpox and zoster.

Comparative immunohistochemical analysis of chickenpox and zoster lesions. Six cases of chickenpox and eight cases of zoster were analyzed by immunohistochemistry using purified polyclonal antibodies generated against VZV proteins (18). Each specimen was analyzed for the presence of gC, a late gene product and component of the virus envelope (15); IE63p, a regulatory protein and component of the virus tegument (14); and ORF29p (13). In these specimens, antibodies to IE63p, ORF29p, and gC detected proteins in the expected intracellular compartments: ORF29p was found in cell nuclei (FIG. 1 ), gC was found in cell membranes and the cytoplasm, and IE63p was found in both the cell nucleus and cytoplasm (data not shown). VZV proteins were detected in epithelial cells, endothelial cells, nerves, and CD43+/CD68+ inflammatory cells in the epidermis and dermis in both chickenpox and zoster cases (FIG. 1 and 2 ). Among the six chickenpox specimens, all were positive for ORF29p, four were positive for IE63p, and five were positive for gC. Among the eight zoster specimens, all were positive for ORF29p, five were positive for IE63p, and five were positive for gC (Table 1).

TABLE 1
Detection of VZV proteins in skin
biopsy samples a
	No. posi-	VZV protein b
Diag-	tive/no.	IE63p	ORF29p	gC
nosis	examined	EP	EN	NE	EP	EN	NE	WBC c	EP	EN	NE
CP	6/6	4	3	0	6	4	2	4	4	5	3
Z	8/8	5	1	0	8	4	0	5	5	5	4
G	0/5	0	0	0	0	0	0	0	0	0	0
HSV-2	0/3	0	0	0	0	0	0	0	0	0	0
a Tissues from patients with clinical and histopathological diagnoses of chickenpox (CP), zoster (Z), Grover's disease (G) or HSV-2 were subjected to immunohistochemical analysis for immediate-early (IE63p), early (ORF29p), and late (gC) virus proteins in epithelial (EP), endothelial (EN), or inflammatory cells expressing CD43 (WBC) or in dermal nerves (NE).
b Results are expressed as the absolute number of biopsy samples with detectable protein. Zero indicates the absence of detectable protein. c VZV-infected WBC from two chickenpox cases and two zoster cases were found to express CD68 and not CD3 or CD20.

These results are consistent with our experience concerning the affinities of these antibodies for their target proteins. Five cases of Grover's disease, a noninfectious dermatosis, and three cases of HSV infection were included as controls and were negative (Table 1), confirming that each antibody signal was specific. Detection of ORF29p, a DNA-binding protein not present in the virion (13), in the nuclei of infected cells demonstrates that VZV replication occurs in endothelial cells, epithelial cells, and cells of the monocyte/macrophage lineage expressing surface CD43 and CD68. Although VZV genomes were detected in circulating lymphocytes of patients with chickenpox and zoster (16, 20) we detected VZV proteins only in CD43+/CD68+ cells and not in cells expressing CD3 or CD20 in these specimens.

No differences in immunohistochemical staining were appreciated between specimens of chickenpox and zoster except for the presence of ORF29p in peripheral nerves in the dermis in two of the chickenpox specimens. ORF29p was detected in the Schwann cells and axons of nerves in these two cases (FIG. 3 A), which included a biopsy sample that was obtained 2 days following the onset of the rash. Cytoplasmic localization of ORF29p is not consistent with the presence of replicating VZV or of formed virions. In contrast, ORF29p was not detected in axons or Schwann cells in the seven zoster biopsy samples with peripheral nerves apparent in the analyzed sections (FIG. 3 C). The absence of ORF29p from axons during zoster was not surprising, as this protein localizes to the nucleus of productively infected cells, including neurons containing reactivating virus (18), and is not detected in virions (13). As expected, gC was found in both axons and Schwann cells of nerves in three chickenpox cases and four zoster cases (FIGS. 3 B and D). Detection of gC indicates the presence of virions or replicating VZV at these sites. The significance of infection of Schwann cells in chickenpox and zoster is unclear. Schwann cells cultivated in tissue culture are permissive for VZV infection (4), but the role of these cells in pathogenesis is not known.

Secretion of ORF29p by infected cells in tissue culture. Clinical and laboratory evidence suggests that DRG are infected via the peripheral nerves during the exanthem of chickenpox (11, 21, 26). Although hematogenous and axonal spread of virus are not mutually exclusive, given the small numbers of VZV-infected circulating PBMCs (16, 20), it seems unlikely that a substantial number of neurons are infected without amplification in the epidermis and dermis. Nonetheless, the exact mechanism by which VZV reaches DRG remains unsettled.

Entry of virus particles into peripheral axons during chickenpox cannot account for the presence of ORF29p at this site because this protein is not a component of the virion (13). Assuming that the virus spreads from the skin to the peripheral nerves during the exanthem, the appearance of ORF29p in the nerve within 2 days of rash onset is surprising because of the distance between the peripheral axon and the sensory neuron in the DRG. By analogy with HSV, it is thought that VZV entering the axon in the epidermis travels by retrograde axonal transport (2) at a rate of 200 to 400 mm/day (28). Additional time would be required for VZV proteins to be produced in the neuron in the DRG and then to travel to the dermis and epidermis by anterograde axonal transport. If the DRG were infected during viremia prior to the onset of the rash, virus replication in the neuron and anterograde axonal transport of VZV proteins could occur. However, this would not explain the presence of ORF29p in peripheral axons, because ORF29p localizes to the nucleus rather than to the cytoplasm during productive infection (18). Moreover, ORF29p was not found in peripheral axons during zoster.

We therefore postulated that ORF29p may be secreted by VZV-infected cells in the dermis or epidermis and enter peripheral axons by endocytosis. In order to test whether ORF29p was secreted by VZV-infected cells, tissue culture media from uninfected human embryonic lung fibroblasts (HELF) or HELF infected with VZV or HSV-1 was clarified by centrifugation and filtration to remove detached cells. Immunoprecipitation with antibodies to ORF29p, ORF21p (a putative VZV accessory DNA binding protein), or ICP8 (the HSV-1 homologue of ORF29p) was performed and the precipitated proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting. ORF29p was detected in culture supernatants of infected cells but not in culture supernatants of uninfected cells (FIG. 4 ). ORF21p was not detected in supernatants of VZV-infected cells, and ICP8 was not detected in supernatants of HSV-1-infected cells. Thus, ORF29p is secreted by infected fibroblasts in tissue culture.

Endocytosis of secreted ORF29p by neurons in tissue culture. Filtered tissue culture medium from VZV-infected HELF and LysoTracker Red DND-99 (Molecular Probes, Eugene, Oreg.), a label for acidic endocytic vesicles, were applied to cultivated human neurons (hNTs) (Stratagene, La Jolla, Calif.) to determine if secreted ORF29p entered neurons by endocytosis. After incubating the hNTs with the filtered culture medium and LysoTracker for 2 h, the cells were examined by immunohistochemistry for the presence of ORF29p. ORF29p was detected in cytoplasmic vesicles ( FIGS. 5A and D ) that colocalized with LysoTracker (FIG. 5 C). ORF29p was not found in untreated hNTs (FIG. 5 E). Therefore, extracellular ORF29p can enter hNTs by endocytosis, supporting our hypothesis that the presence of this protein in peripheral axons may result from its assimilation from surrounding cells that are infected with VZV.

Our results illustrate key steps of VZV pathogenesis. During chickenpox, VZV infects epithelial cells, endothelial cells, cells of the monocyte/macrophage lineage, and nerves of the skin. After infecting the neuron, the virus enters latency. In some individuals, the virus reactivates in one or more neurons, travels via the axon to the skin, and infects the epithelial cells.

In addition, endothelial cells are infected in zoster, which could potentially spread virus to other areas. That VZV does not typically spread outside of the dermatome during zoster implies that host immunity effectively halts cell-to-cell spread. This study suggests that entry of VZV into the nervous system during primary infection may not rely solely on axonal transport of mature virions from the skin during chickenpox, because ORF29p was present in axons early in the course of the rash.

REFERENCES

1. Annunziato, P., O. Lungu, A. Gershon, D. Silvers, P. LaRussa, and S. Silverstein. 1996. In situ hybridization detection of varicella zoster virus in paraffin-embedded skin biopsy samples. Clin. Diagn. Virol. 7:69-76.

2. Arvin, A. 1996. Varicella-zoster virus, p. 2547-2585. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.

3. Asano, Y., N. Itakura, Y. Hiroishi, S. Hirose, T. Nagai, T. Ozaki, T. Yazaki, Y. Yamanishi, and M. Takahashi. 1985. Viremia is present in incubation period in nonimmunocompromised children with varicella. J. Pediatr. 106: 69-71.

4. Assouline, J. G., M. J. Levin, E. O. Major, B. Forghani, S. Straus, and J. M. Ostrove. 1990. Varicella-zoster virus infection of human astrocytes, Schwann cells, and neurons. Virology 179:834-843.

5. Cohen, J., and S. Straus. 1996. Varicella-zoster virus and its replication, p. 2525-2546. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.

6. Cohrs, R. J., M. Barbour, and D. Gilden. 1996. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J.Virol. 70:2789-2796.

7. Cohrs, R. J., M. B. Barbour, R. Mahlingham, M. Wellish, and D. Gilden. 1995. Varicella-zoster virus (VZV) transcription during latency in human ganglia: prevalence of VZV gene 21 transcripts in latently infected human ganglia. J. Virol. 69:2674-2678.

8. Cohrs, R. J., K. Srock, M. B. Barbour, G. Owens, R. Mahlingham, M. Devlin, M. Wellish, and D. Gilden. 1994. Varicella-zoster virus (VZV) transcription during latency in human ganglia: construction of a cDNA library from latently infected human trigeminal ganglia and detection of a VZV transcript. J. Virol. 68:7900-7908.

9. Croen, K. D., J. M. Ostrove, L. Y. Dragovic, and S. E. Straus. 1988. Patterns of gene expression and sites of latency in human ganglia are different for varicella-zoster and herpes simplex viruses. Proc. Natl. Acad. Sci. USA 85:9773-9777.

10. Esiri, M., and A. Tomlinson. 1972. Herpes zoster: demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron micros-copy. J. Neurol. Sci. 15:35-48.

11. Hope-Simpson, R. E. 1965. The nature of herpes zoster: a long term study and a new hypothesis. Proc. R. Soc. Med. 58:9-20.

12. Kennedy, P., E. Grinfeld, and J. Gow. 1998. Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc. Natl. Acad. Sci. USA 95:4658-4662.

13. Kinchington, P., J. Hougland, A. Arvin, W. Ruyechan, and J. Hay. 1992. The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J. Virol. 66:359-366.

14. Kinchington, P. R., D. Bookey, and S. E. Turse. 1995. The transcriptional regulatory proteins encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF 61, are associated with purified virus particles. J. Virol. 69:4274-4282.

15. Kinchington, P. R., P. Ling, M. Pensiero, W. T. Ruyechan, and J. Hay. 1990. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J. Virol. 64:4540-4548.

16. Koropchak, C., G. Graham, J. Palmer, M. Winsberg, S. Ting, M. Wallace, C. Prober, and A. Arvin. 1991. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J. Infect. Dis. 163:1016-1022.

17. Lungu, O., P. Annunziato, A. Gershon, S. Stegatis, D. Josefson, P. LaRussa, and S. Silverstein. 1995. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc. Natl. Acad. Sci. USA 92:10980-10984.

18. Lungu, O., C. Panagiotidis, P. Annunziato, A. Gershon, and S. Silverstein. 1998. Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc. Natl. Acad. Sci. USA 95:7080-7085.

19. Mahalingam, R., M. Wellish, R. Cohrs, S. Debrus, J. Piette, B. Rentier, and D. Gilden. 1996. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc. Natl. Acad. Sci. USA 93:2122-2124.

20. Mainka, C., B. Fuss, H. Geiger, H. Hofelmayr, and M. Wolff. 1998. Characterization of viremia at different stages of varicella-zoster virus infection. J. Med. Virol. 46:91-98.

21. Mazur, H., and R. Dolin. 1978. Herpes zoster at the NIH: a 20 year experience. Am. J. Med. 65:738-744.

22. Meier, J. L., R. P. Holman, K. D. Croen, J. E. Smialek, and S. E. Straus. 1993. Varicella-zoster virus transcription in human trigeminal ganglia. Virology 193 :193-200.

23. Nikkels, A., P. Delvenne, S. Debrus, C. Sadzot-Delvaux, J. Piette, B. Rentier, and G. Pierard. 1995. Distribution of varicella-zoster virus gpI and gpII and corresponding genome sequences in the skin. J. Med. Virol. 46:91-6.

24. Nikkels, A. F., B. Rentier, and G. E. Pierard. 1997. Chronic varicella-zoster virus skin lesions in patients with human immunodeficiency virus are related to decreased expression of gE and gB. J. Infect. Dis. 176:261-264.

25. Nikkels, A. F., S. Debrus, C. Sadzot-Delvaux, J. Piette, P. Delvenne, B. Rentier, and G. E. Pierard. 1993. Comparative immunohistochemical study of herpes simplex and varicella-zoster infections. Virchows Arch. A 422:121-126.

26. Sadzot-Delvaux, C., M.-P. Merville-Louis, P. Delree, P. Marc, G. Moonen, and B. Rentier. 1990. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J. Neurosci. Res. 26:83-89.

27. Sawyer, M. H., Y. N. Wu, C. J. Chamberlin, C. Burgos, S. K. Brodine, W. A. Bowler, A. LaRocco, E. C. Oldfield, and M. R. Wallace. 1992. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J. Infect. Dis. 166:885-888.

28. Schwartz, J. 1984. Biochemical control mechanisms in synaptic transmissions, p. 121-131. In E. Kandel and J. Schwartz (ed.), Principles of neural science. Elsevier Science Publishing, New York, N.Y.

29. Tyzzer, E. E. 1996. The histology of skin lesions in varicella. J. Med. Res. 14:361-392.

30. Sambrook, J., et al. 1989. Molecular Cloning: A laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press.

2 1 3610 DNA Varicella zoster CDS (1)..(3609) 1atg gaa aat act cag aag act gtg aca gtg ccc acg ggg ccc ctg ggt 48Met Glu Asn Thr Gln Lys Thr Val Thr Val Pro Thr Gly Pro Leu Gly1 5 10 15tac gtt tat gcg tgc cgg gtt gaa gat ttg gat ctg gag gaa att tca 96Tyr Val Tyr Ala Cys Arg Val Glu Asp Leu Asp Leu Glu Glu Ile Ser 20 25 30ttt ttg gcc gct cgt agc acg gac tct gat ttg gct tta tta cct ttg 144Phe Leu Ala Ala Arg Ser Thr Asp Ser Asp Leu Ala Leu Leu Pro Leu 35 40 45atg cgt aat ttg acc gtg gaa aaa act ttt aca tcc agc ctg gcg gtg 192Met Arg Asn Leu Thr Val Glu Lys Thr Phe Thr Ser Ser Leu Ala Val 50 55 60gtt tct gga gca cgc act acg ggt ctt gcc gga gct ggt att acc tta 240Val Ser Gly Ala Arg Thr Thr Gly Leu Ala Gly Ala Gly Ile Thr Leu65 70 75 80aaa ctc act acc agt cat ttc tat cca tct gtc ttt gtc ttt cac gga 288Lys Leu Thr Thr Ser His Phe Tyr Pro Ser Val Phe Val Phe His Gly 85 90 95ggc aaa cac gtt tta ccc agc tcc gcg gcc cca aat ctc aca cgc gcg 336Gly Lys His Val Leu Pro Ser Ser Ala Ala Pro Asn Leu Thr Arg Ala 100 105 110tgt aac gcg gct cga gaa cgg ttt ggg ttt tca cgc tgc caa ggg cct 384Cys Asn Ala Ala Arg Glu Arg Phe Gly Phe Ser Arg Cys Gln Gly Pro 115 120 125cct gtt gac ggt gct gtt gag acg acc ggc gct gag ata tgc acc cgc 432Pro Val Asp Gly Ala Val Glu Thr Thr Gly Ala Glu Ile Cys Thr Arg 130 135 140ctt gga tta gag cca gaa aat aca ata tta tac ttg gtg gtc acg gca 480Leu Gly Leu Glu Pro Glu Asn Thr Ile Leu Tyr Leu Val Val Thr Ala145 150 155 160ttg ttt aag gaa gcc gta ttt atg tgc aac gtg ttt ctg cat tat gga 528Leu Phe Lys Glu Ala Val Phe Met Cys Asn Val Phe Leu His Tyr Gly 165 170 175gga ctc gat att gtt cat att aac cat ggg gat gtt ata cgt ata ccg 576Gly Leu Asp Ile Val His Ile Asn His Gly Asp Val Ile Arg Ile Pro 180 185 190tta ttt ccg gta caa ctt ttc atg ccc gat gtt aac cgt ctg gta ccc 624Leu Phe Pro Val Gln Leu Phe Met Pro Asp Val Asn Arg Leu Val Pro 195 200 205gac cca ttc aac act cat cac agg tct atc gga gag ggt ttt gta tac 672Asp Pro Phe Asn Thr His His Arg Ser Ile Gly Glu Gly Phe Val Tyr 210 215 220cca aca ccc ttt tat aac acc ggg ttg tgc cat tta ata cat gac tgt 720Pro Thr Pro Phe Tyr Asn Thr Gly Leu Cys His Leu Ile His Asp Cys225 230 235 240gtt att gct ccc atg gcc gtt gcc ttg cgc gtc aga aat gta act gcc 768Val Ile Ala Pro Met Ala Val Ala Leu Arg Val Arg Asn Val Thr Ala 245 250 255gtc gcc cga gga gcg gcc cac ctt gct ttt gat gaa aat cac gag ggg 816Val Ala Arg Gly Ala Ala His Leu Ala Phe Asp Glu Asn His Glu Gly 260 265 270gca gta ctc ccc cct gac att acg tac acg tat ttt cag tcc tct tca 864Ala Val Leu Pro Pro Asp Ile Thr Tyr Thr Tyr Phe Gln Ser Ser Ser 275 280 285agt gga acc act acc gcc cgt gga gcg cgt cga aac gat gtc aac tcc 912Ser Gly Thr Thr Thr Ala Arg Gly Ala Arg Arg Asn Asp Val Asn Ser 290 295 300acg tct aag cct agc cca tcg ggg ggg ttt gaa aga cgg ttg gcg tct 960Thr Ser Lys Pro Ser Pro Ser Gly Gly Phe Glu Arg Arg Leu Ala Ser305 310 315 320att atg gcc gct gac aca gcc ttg cac gca gaa gtt ata ttc aac act 1008Ile Met Ala Ala Asp Thr Ala Leu His Ala Glu Val Ile Phe Asn Thr 325 330 335gga att tac gaa gaa act cca aca gat atc aaa gaa tgg cca atg ttt 1056Gly Ile Tyr Glu Glu Thr Pro Thr Asp Ile Lys Glu Trp Pro Met Phe 340 345 350ata ggc atg gag ggc act ttg cca agg cta aac gct ctg ggg tca tat 1104Ile Gly Met Glu Gly Thr Leu Pro Arg Leu Asn Ala Leu Gly Ser Tyr 355 360 365acc gct cgt gtg gcc ggg gtc att ggt gcg atg gtt ttc agc cca aat 1152Thr Ala Arg Val Ala Gly Val Ile Gly Ala Met Val Phe Ser Pro Asn 370 375 380tct gcg ttg tat cta act gag gtg gag gat agc ggg atg acc gaa gcc 1200Ser Ala Leu Tyr Leu Thr Glu Val Glu Asp Ser Gly Met Thr Glu Ala385 390 395 400aag gat ggg gga ccg ggt cca tca ttt aat cga ttt tac cag ttt gcc 1248Lys Asp Gly Gly Pro Gly Pro Ser Phe Asn Arg Phe Tyr Gln Phe Ala 405 410 415gga cct cat tta gct gcg aat ccc caa aca gat cga gat ggc cac gtt 1296Gly Pro His Leu Ala Ala Asn Pro Gln Thr Asp Arg Asp Gly His Val 420 425 430cta tcc agt cag tct acg ggt tca tca aac aca gag ttt agc gtg gat 1344Leu Ser Ser Gln Ser Thr Gly Ser Ser Asn Thr Glu Phe Ser Val Asp 435 440 445tat ttg gca ctc att tgt gga ttt gga gca ccc ctg ttg gcg cga ctg 1392Tyr Leu Ala Leu Ile Cys Gly Phe Gly Ala Pro Leu Leu Ala Arg Leu 450 455 460ctt ttt tat cta gaa cgc tgt gac gct ggt gcg ttt aca ggg ggt cac 1440Leu Phe Tyr Leu Glu Arg Cys Asp Ala Gly Ala Phe Thr Gly Gly His465 470 475 480ggg gat gcg tta aaa tat gtt acg ggg acc ttt gac tct gaa att cca 1488Gly Asp Ala Leu Lys Tyr Val Thr Gly Thr Phe Asp Ser Glu Ile Pro 485 490 495tgt agt tta tgt gaa aaa cac acg cgg ccg gta tgc gct cac aca aca 1536Cys Ser Leu Cys Glu Lys His Thr Arg Pro Val Cys Ala His Thr Thr 500 505 510gta cac cga ctt aga caa cgc atg ccg cga ttt gga caa gcc acc cgt 1584Val His Arg Leu Arg Gln Arg Met Pro Arg Phe Gly Gln Ala Thr Arg 515 520 525caa cct att ggg gtg ttt gga aca atg aac agc caa tat agc gac tgc 1632Gln Pro Ile Gly Val Phe Gly Thr Met Asn Ser Gln Tyr Ser Asp Cys 530 535 540gat cct cta gga aac tat gct cca tat tta atc ctt cga aaa ccc ggg 1680Asp Pro Leu Gly Asn Tyr Ala Pro Tyr Leu Ile Leu Arg Lys Pro Gly545 550 555 560gat caa acg gaa gca gca aag gca acc atg cag gac act tat agg gct 1728Asp Gln Thr Glu Ala Ala Lys Ala Thr Met Gln Asp Thr Tyr Arg Ala 565 570 575aca cta gaa cgc ttg ttt atc gat cta gaa caa gag cga cta ctg gat 1776Thr Leu Glu Arg Leu Phe Ile Asp Leu Glu Gln Glu Arg Leu Leu Asp 580 585 590cgc ggt gcc cca tgt tct tcc gag gga cta tcg tct gtc att gtg gat 1824Arg Gly Ala Pro Cys Ser Ser Glu Gly Leu Ser Ser Val Ile Val Asp 595 600 605cat cca acg ttt cgt cgc ata tta gac aca ctg cgt gcg cgt ata gaa 1872His Pro Thr Phe Arg Arg Ile Leu Asp Thr Leu Arg Ala Arg Ile Glu 610 615 620cag aca aca aca caa ttt atg aaa gtg ttg gtt gag acc cgc gat tat 1920Gln Thr Thr Thr Gln Phe Met Lys Val Leu Val Glu Thr Arg Asp Tyr625 630 635 640aag atc cgt gaa gga tta tcc gaa gcc acc cat tca atg gcg tta acg 1968Lys Ile Arg Glu Gly Leu Ser Glu Ala Thr His Ser Met Ala Leu Thr 645 650 655ttt gat cca tac tca gga gca ttt tgt ccc att acc aat ttt tta gtt 2016Phe Asp Pro Tyr Ser Gly Ala Phe Cys Pro Ile Thr Asn Phe Leu Val 660 665 670aaa cga aca cac cta gcc gtg gta caa gac tta gca tta agc caa tgt 2064Lys Arg Thr His Leu Ala Val Val Gln Asp Leu Ala Leu Ser Gln Cys 675 680 685cat tgt gta ttt tac gga cag caa gtt gag ggg cgg aac ttt cgt aac 2112His Cys Val Phe Tyr Gly Gln Gln Val Glu Gly Arg Asn Phe Arg Asn 690 695 700caa ttc caa cct gtt ttg cgg cgg cgt ttt gtt gac ctg ttt aat ggg 2160Gln Phe Gln Pro Val Leu Arg Arg Arg Phe Val Asp Leu Phe Asn Gly705 710 715 720ggg ttt ata tca aca cgc tct ata acc gta aca tta tct gaa ggt cct 2208Gly Phe Ile Ser Thr Arg Ser Ile Thr Val Thr Leu Ser Glu Gly Pro 725 730 735gta tcc gcc cca aat ccg aca ttg gga caa gac gcg ccc gcg ggg cgt 2256Val Ser Ala Pro Asn Pro Thr Leu Gly Gln Asp Ala Pro Ala Gly Arg 740 745 750acc ttt gat ggg gat tta gcg cgc gta agc gtg gaa gtt att cgg gat 2304Thr Phe Asp Gly Asp Leu Ala Arg Val Ser Val Glu Val Ile Arg Asp 755 760 765ata cga gtt aaa aat agg gtc gtt ttt tca ggt aac tgt aca aat ctc 2352Ile Arg Val Lys Asn Arg Val Val Phe Ser Gly Asn Cys Thr Asn Leu 770 775 780tct gag gca gcc cgg gca agg ctt gta ggc ctt gca agt gcg tac caa 2400Ser Glu Ala Ala Arg Ala Arg Leu Val Gly Leu Ala Ser Ala Tyr Gln785 790 795 800cgc caa gaa aaa aga gtg gat atg tta cac ggg gcc cta ggg ttt ttg 2448Arg Gln Glu Lys Arg Val Asp Met Leu His Gly Ala Leu Gly Phe Leu 805 810 815ctt aaa cag ttt cac ggc ctg tta ttt cct cgg ggt atg cca cca aac 2496Leu Lys Gln Phe His Gly Leu Leu Phe Pro Arg Gly Met Pro Pro Asn 820 825 830agt aaa tcc ccc aac ccg cag tgg ttt tgg acc ctg tta caa cgc aac 2544Ser Lys Ser Pro Asn Pro Gln Trp Phe Trp Thr Leu Leu Gln Arg Asn 835 840 845cag atg ccg gca gat aaa ctt aca cac gaa gag att acc act att gca 2592Gln Met Pro Ala Asp Lys Leu Thr His Glu Glu Ile Thr Thr Ile Ala 850 855 860gct gtt aaa cgg ttt acc gag gaa tat gca gca ata aac ttt att aat 2640Ala Val Lys Arg Phe Thr Glu Glu Tyr Ala Ala Ile Asn Phe Ile Asn865 870 875 880cta ccc cca acc tgc ata gga gaa tta gcc cag ttt tat atg gca aat 2688Leu Pro Pro Thr Cys Ile Gly Glu Leu Ala Gln Phe Tyr Met Ala Asn 885 890 895ctt att ctt aaa tac tgc gat cat tca cag tac ctt ata aat acc tta 2736Leu Ile Leu Lys Tyr Cys Asp His Ser Gln Tyr Leu Ile Asn Thr Leu 900 905 910act tct ata att acg ggt gcc agg cgc ccg cgt gac cca tca tcc gtt 2784Thr Ser Ile Ile Thr Gly Ala Arg Arg Pro Arg Asp Pro Ser Ser Val 915 920 925ttg cat tgg att cgt aaa gat gtc acg tcc gcc gcg gac ata gaa acc 2832Leu His Trp Ile Arg Lys Asp Val Thr Ser Ala Ala Asp Ile Glu Thr 930 935 940caa gca aag gcg ctt ctt gaa aaa acg gaa aac tta ccg gaa tta tgg 2880Gln Ala Lys Ala Leu Leu Glu Lys Thr Glu Asn Leu Pro Glu Leu Trp945 950 955 960act acg gct ttt act tca act cat tta gtc cgc gcg gcc atg aat caa 2928Thr Thr Ala Phe Thr Ser Thr His Leu Val Arg Ala Ala Met Asn Gln 965 970 975cgt ccc atg gtc gtt tta gga ata agc att agt aaa tat cac gga gcg 2976Arg Pro Met Val Val Leu Gly Ile Ser Ile Ser Lys Tyr His Gly Ala 980 985 990gca gga aac aac cgc gtc ttt cag gca ggg aat tgg agc ggt tta aac 3024Ala Gly Asn Asn Arg Val Phe Gln Ala Gly Asn Trp Ser Gly Leu Asn 995 1000 1005ggg ggt aaa aat gta tgc ccg cta ttt aca ttt gat cgc act cgc 3069Gly Gly Lys Asn Val Cys Pro Leu Phe Thr Phe Asp Arg Thr Arg 1010 1015 1020cgt ttt ata ata gca tgt cct aga gga ggt ttt atc tgc ccc gta 3114Arg Phe Ile Ile Ala Cys Pro Arg Gly Gly Phe Ile Cys Pro Val 1025 1030 1035aca ggt ccc tcg tcg gga aat cga gaa acc acc cta tcc gac caa 3159Thr Gly Pro Ser Ser Gly Asn Arg Glu Thr Thr Leu Ser Asp Gln 1040 1045 1050gtt cgc ggt ata att gtc agt ggc ggg gcc atg gtt caa tta gcc 3204Val Arg Gly Ile Ile Val Ser Gly Gly Ala Met Val Gln Leu Ala 1055 1060 1065ata tac gcc acg gtt gtg cgt gca gtg ggc gct cga gca caa cat 3249Ile Tyr Ala Thr Val Val Arg Ala Val Gly Ala Arg Ala Gln His 1070 1075 1080atg gca ttt gac gac tgg tta agt ctt aca gac gat gag ttt tta 3294Met Ala Phe Asp Asp Trp Leu Ser Leu Thr Asp Asp Glu Phe Leu 1085 1090 1095gcc aga gac ttg gag gag tta cac gac cag att atc caa acc ctg 3339Ala Arg Asp Leu Glu Glu Leu His Asp Gln Ile Ile Gln Thr Leu 1100 1105 1110gaa acg ccc tgg acc gta gaa ggc gct cta gaa gca gta aag att 3384Glu Thr Pro Trp Thr Val Glu Gly Ala Leu Glu Ala Val Lys Ile 1115 1120 1125cta gat gaa aaa acg aca gcg gga gat ggg gaa acc ccc aca aac 3429Leu Asp Glu Lys Thr Thr Ala Gly Asp Gly Glu Thr Pro Thr Asn 1130 1135 1140cta gca ttt aat ttt gat tct tgt gaa cca agc cat gac acc aca 3474Leu Ala Phe Asn Phe Asp Ser Cys Glu Pro Ser His Asp Thr Thr 1145 1150 1155tct aac gta tta aac att tca ggg tca aac att tca ggg tca act 3519Ser Asn Val Leu Asn Ile Ser Gly Ser Asn Ile Ser Gly Ser Thr 1160 1165 1170gtc cct ggt ctt aaa cga ccc ccc gaa gat gac gaa ctc ttt gat 3564Val Pro Gly Leu Lys Arg Pro Pro Glu Asp Asp Glu Leu Phe Asp 1175 1180 1185ctt agt ggt att ccc ata aaa cat ggg aac att aca atg gaa atg a 3610Leu Ser Gly Ile Pro Ile Lys His Gly Asn Ile Thr Met Glu Met 1190 1195 1200 2 1203 PRT Varicella zoster 2Met Glu Asn Thr Gln Lys Thr Val Thr Val Pro Thr Gly Pro Leu Gly1 5 10 15Tyr Val Tyr Ala Cys Arg Val Glu Asp Leu Asp Leu Glu Glu Ile Ser 20 25 30Phe Leu Ala Ala Arg Ser Thr Asp Ser Asp Leu Ala Leu Leu Pro Leu 35 40 45Met Arg Asn Leu Thr Val Glu Lys Thr Phe Thr Ser Ser Leu Ala Val 50 55 60Val Ser Gly Ala Arg Thr Thr Gly Leu Ala Gly Ala Gly Ile Thr Leu65 70 75 80Lys Leu Thr Thr Ser His Phe Tyr Pro Ser Val Phe Val Phe His Gly 85 90 95Gly Lys His Val Leu Pro Ser Ser Ala Ala Pro Asn Leu Thr Arg Ala 100 105 110Cys Asn Ala Ala Arg Glu Arg Phe Gly Phe Ser Arg Cys Gln Gly Pro 115 120 125Pro Val Asp Gly Ala Val Glu Thr Thr Gly Ala Glu Ile Cys Thr Arg 130 135 140Leu Gly Leu Glu Pro Glu Asn Thr Ile Leu Tyr Leu Val Val Thr Ala145 150 155 160Leu Phe Lys Glu Ala Val Phe Met Cys Asn Val Phe Leu His Tyr Gly 165 170 175Gly Leu Asp Ile Val His Ile Asn His Gly Asp Val Ile Arg Ile Pro 180 185 190Leu Phe Pro Val Gln Leu Phe Met Pro Asp Val Asn Arg Leu Val Pro 195 200 205Asp Pro Phe Asn Thr His His Arg Ser Ile Gly Glu Gly Phe Val Tyr 210 215 220Pro Thr Pro Phe Tyr Asn Thr Gly Leu Cys His Leu Ile His Asp Cys225 230 235 240Val Ile Ala Pro Met Ala Val Ala Leu Arg Val Arg Asn Val Thr Ala 245 250 255Val Ala Arg Gly Ala Ala His Leu Ala Phe Asp Glu Asn His Glu Gly 260 265 270Ala Val Leu Pro Pro Asp Ile Thr Tyr Thr Tyr Phe Gln Ser Ser Ser 275 280 285Ser Gly Thr Thr Thr Ala Arg Gly Ala Arg Arg Asn Asp Val Asn Ser 290 295 300Thr Ser Lys Pro Ser Pro Ser Gly Gly Phe Glu Arg Arg Leu Ala Ser305 310 315 320Ile Met Ala Ala Asp Thr Ala Leu His Ala Glu Val Ile Phe Asn Thr 325 330 335Gly Ile Tyr Glu Glu Thr Pro Thr Asp Ile Lys Glu Trp Pro Met Phe 340 345 350Ile Gly Met Glu Gly Thr Leu Pro Arg Leu Asn Ala Leu Gly Ser Tyr 355 360 365Thr Ala Arg Val Ala Gly Val Ile Gly Ala Met Val Phe Ser Pro Asn 370 375 380Ser Ala Leu Tyr Leu Thr Glu Val Glu Asp Ser Gly Met Thr Glu Ala385 390 395 400Lys Asp Gly Gly Pro Gly Pro Ser Phe Asn Arg Phe Tyr Gln Phe Ala 405 410 415Gly Pro His Leu Ala Ala Asn Pro Gln Thr Asp Arg Asp Gly His Val 420 425 430Leu Ser Ser Gln Ser Thr Gly Ser Ser Asn Thr Glu Phe Ser Val Asp 435 440 445Tyr Leu Ala Leu Ile Cys Gly Phe Gly Ala Pro Leu Leu Ala Arg Leu 450 455 460Leu Phe Tyr Leu Glu Arg Cys Asp Ala Gly Ala Phe Thr Gly Gly His465 470 475 480Gly Asp Ala Leu Lys Tyr Val Thr Gly Thr Phe Asp Ser Glu Ile Pro 485 490 495Cys Ser Leu Cys Glu Lys His Thr Arg Pro Val Cys Ala His Thr Thr 500 505 510Val His Arg Leu Arg Gln Arg Met Pro Arg Phe Gly Gln Ala Thr Arg 515 520 525Gln Pro Ile Gly Val Phe Gly Thr Met Asn Ser Gln Tyr Ser Asp Cys 530 535 540Asp Pro Leu Gly Asn Tyr Ala Pro Tyr Leu Ile Leu Arg Lys Pro Gly545 550 555 560Asp Gln Thr Glu Ala Ala Lys Ala Thr Met Gln Asp Thr Tyr Arg Ala 565 570 575Thr Leu Glu Arg Leu Phe Ile Asp Leu Glu Gln Glu Arg Leu Leu Asp 580 585 590Arg Gly Ala Pro Cys Ser Ser Glu Gly Leu Ser Ser Val Ile Val Asp 595 600 605His Pro Thr Phe Arg Arg Ile Leu Asp Thr Leu Arg Ala Arg Ile Glu 610 615 620Gln Thr Thr Thr Gln Phe Met Lys Val Leu Val Glu Thr Arg Asp Tyr625 630 635 640Lys Ile Arg Glu Gly Leu Ser Glu Ala Thr His Ser Met Ala Leu Thr 645 650 655Phe Asp Pro Tyr Ser Gly Ala Phe Cys Pro Ile Thr Asn Phe Leu Val 660 665 670Lys Arg Thr His Leu Ala Val Val Gln Asp Leu Ala Leu Ser Gln Cys 675 680 685His Cys Val Phe Tyr Gly Gln Gln Val Glu Gly Arg Asn Phe Arg Asn 690 695 700Gln Phe Gln Pro Val Leu Arg Arg Arg Phe Val Asp Leu Phe Asn Gly705 710 715 720Gly Phe Ile Ser Thr Arg Ser Ile Thr Val Thr Leu Ser Glu Gly Pro 725 730 735Val Ser Ala Pro Asn Pro Thr Leu Gly Gln Asp Ala Pro Ala Gly Arg 740 745 750Thr Phe Asp Gly Asp Leu Ala Arg Val Ser Val Glu Val Ile Arg Asp 755 760 765Ile Arg Val Lys Asn Arg Val Val Phe Ser Gly Asn Cys Thr Asn Leu 770 775 780Ser Glu Ala Ala Arg Ala Arg Leu Val Gly Leu Ala Ser Ala Tyr Gln785 790 795 800Arg Gln Glu Lys Arg Val Asp Met Leu His Gly Ala Leu Gly Phe Leu 805 810 815Leu Lys Gln Phe His Gly Leu Leu Phe Pro Arg Gly Met Pro Pro Asn 820 825 830Ser Lys Ser Pro Asn Pro Gln Trp Phe Trp Thr Leu Leu Gln Arg Asn 835 840 845Gln Met Pro Ala Asp Lys Leu Thr His Glu Glu Ile Thr Thr Ile Ala 850 855 860Ala Val Lys Arg Phe Thr Glu Glu Tyr Ala Ala Ile Asn Phe Ile Asn865 870 875 880Leu Pro Pro Thr Cys Ile Gly Glu Leu Ala Gln Phe Tyr Met Ala Asn 885 890 895Leu Ile Leu Lys Tyr Cys Asp His Ser Gln Tyr Leu Ile Asn Thr Leu 900 905 910Thr Ser Ile Ile Thr Gly Ala Arg Arg Pro Arg Asp Pro Ser Ser Val 915 920 925Leu His Trp Ile Arg Lys Asp Val Thr Ser Ala Ala Asp Ile Glu Thr 930 935 940Gln Ala Lys Ala Leu Leu Glu Lys Thr Glu Asn Leu Pro Glu Leu Trp945 950 955 960Thr Thr Ala Phe Thr Ser Thr His Leu Val Arg Ala Ala Met Asn Gln 965 970 975Arg Pro Met Val Val Leu Gly Ile Ser Ile Ser Lys Tyr His Gly Ala 980 985 990Ala Gly Asn Asn Arg Val Phe Gln Ala Gly Asn Trp Ser Gly Leu Asn 995 1000 1005Gly Gly Lys Asn Val Cys Pro Leu Phe Thr Phe Asp Arg Thr Arg 1010 1015 1020Arg Phe Ile Ile Ala Cys Pro Arg Gly Gly Phe Ile Cys Pro Val 1025 1030 1035Thr Gly Pro Ser Ser Gly Asn Arg Glu Thr Thr Leu Ser Asp Gln 1040 1045 1050Val Arg Gly Ile Ile Val Ser Gly Gly Ala Met Val Gln Leu Ala 1055 1060 1065Ile Tyr Ala Thr Val Val Arg Ala Val Gly Ala Arg Ala Gln His 1070 1075 1080Met Ala Phe Asp Asp Trp Leu Ser Leu Thr Asp Asp Glu Phe Leu 1085 1090 1095Ala Arg Asp Leu Glu Glu Leu His Asp Gln Ile Ile Gln Thr Leu 1100 1105 1110Glu Thr Pro Trp Thr Val Glu Gly Ala Leu Glu Ala Val Lys Ile 1115 1120 1125Leu Asp Glu Lys Thr Thr Ala Gly Asp Gly Glu Thr Pro Thr Asn 1130 1135 1140Leu Ala Phe Asn Phe Asp Ser Cys Glu Pro Ser His Asp Thr Thr 1145 1150 1155Ser Asn Val Leu Asn Ile Ser Gly Ser Asn Ile Ser Gly Ser Thr 1160 1165 1170Val Pro Gly Leu Lys Arg Pro Pro Glu Asp Asp Glu Leu Phe Asp 1175 1180 1185Leu Ser Gly Ile Pro Ile Lys His Gly Asn Ile Thr Met Glu Met 1190 1195 1200

Claims

1. A composition of matter comprising Varicella-Zoster Virus 29p protein having polypeptide covalently bound its N- or C-terminus, which composition of matter enters a mammalian cell upon contact therewith, and wherein the Varicella-Zoster Virus 29p protein comprises the amino acid sequence set forth in SEQ ID NO:2.

2. A composition of matter comprising a Varicella-Zoster Virus 29p protein having a lipid-soluble moiety covalently bound to its N- or C-terminus, wherein the Varicella-Zoster Virus 29p protein comprises the amino acid sequence set forth in SEQ ID NO:2, and wherein the lipid-soluble moiety permits the 29p protein to be anchored to a lipid membrane.

3. A lipid vesicle comprising the composition of matter of claim 2 anchored thereto via its lipid-soluble moiety, such that the 29p protein is situated on the vesicle's outer surface and facilitates delivery of the vesicle's contents into a eukaryotic cell when the vesicle is contacted therewith.

4. The lipid vesicle of claim 3, wherein vesicle's contents comprise an agent.